Clinical trial
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy and in Combination With Chemotherapy and/or Immunotherapy in Subjects With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma Whose Are Claudin (CLDN) 18.2 Positive
NCT03505320 is registered in ClinicalTrials.gov with Astellas Pharma Global Development, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy and in Combination With Chemotherapy and/or Immunotherapy in Subjects With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma Whose Are Claudin (CLDN) 18.2 Positive
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- June 29, 2018
- Completion date
- May 31, 2028
- Enrollment
- 143 (actual)
- Sites
- 21
Conditions
As the registry lists them; a condition with its own page is linked.
gastric cancer, gastro-esophageal junction (gej) cancer, pharmacokinetics of fluorouracil bolus (5-fu), pharmacokinetics of oxaliplatin, pharmacokinetics of zolbetuximab